The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Evaluation of AJCC Tumor Staging for Cutaneous Squamous Cell Carcinoma and a Proposed Alternative Tumor Staging System
Abstract
IMPORTANCE: This study proposes an alternative tumor staging system for cutaneous squamous cell carcinoma (CSCC) that more precisely defines the small subset of tumors with a high risk of metastasis and death. OBJECTIVE: To identify risk factors for poor outcomes in CSCC and evaluate the 2010 American Joint Committee on Cancer (AJCC) tumor (T) staging system's ability to stratify occurrence of these outcomes. DESIGN: Retrospective cohort study. SETTING: A single academic hospital. PARTICIPANTS: Study participants were identified via a pathology and dermatopathology database search for patients diagnosed as having high-risk CSCC. RESULTS: Two hundred fifty-six primary high-risk CSCCs were included. Outcomes for AJCC tumor stages T2 to T4 were statistically indistinguishable because only 4 cases (<2% of the cohort) were AJCC stages T3 or T4, which require bone invasion. Subsequently, the bulk of poor outcomes (83% of nodal metastases, 92% of deaths from CSCC) occurred in AJCC stage T2 cases. An alternative tumor staging system was developed with the aim of better stratifying this stage T2 group. Four risk factors were found to be statistically independent prognostic factors for at least 2 outcomes of interest in multivariate modeling. These factors (poor differentiation, perineural invasion, tumor diameter ≥2 cm, invasion beyond subcutaneous fat) were incorporated in the alternative staging with 0 factors indicating T1, 1 factor indicating T2a; 2 to 3 factors, T2b; and 4 factors or bone invasion, T3. Stages T2a and T2b significantly differed in incidences of all 4 end points. Stage T2b tumors comprised only 19% of the cohort but accounted for 72% of nodal metastases and 83% of deaths from CSCC. CONCLUSIONS AND RELEVANCE: The proposed alternative tumor staging system offers improved prognostic discrimination via stratification of stage T2 tumors. Validation in other cohorts is needed. Meanwhile, stage T2b tumors are responsible for most poor outcomes and may be a focus of high-risk CSCC study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Rowe, D. E., Carroll, R. J., & Day, C. L. (1992) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(92)70144-5 · Cited by 1,503
Incidence Estimate of Nonmelanoma Skin Cancer in the United States, 2006
Rogers, H. W., Weinstock, M. A., Harris, A. R., Hinckley, M. R., Feldman, S. R., Fleischer, A. B., & Coldiron, B. M. (2010) · Archives of Dermatology · doi:10.1001/archdermatol.2010.19 · Cited by 1,185
Brantsch, K. D., Meisner, C., Schönfisch, B., Trilling, B., Wehner-Caroli, J., Röcken, M., & Breuninger, H. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70178-5 · Cited by 1,054
Mortality Risk From Squamous Cell Skin Cancer
Clayman, G. L., Lee, J. J., Holsinger, F. C., Zhou, X., Duvic, M., El-Naggar, A. K., Prieto, V. G., Altamirano, E., Tucker, S. L., Strom, S. S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.155 · Cited by 392
Veness, M. J., Morgan, G. J., Palme, C. E., & Gebski, V. (2005) · The Laryngoscope · doi:10.1097/01.mlg.0000158349.64337.ed · Cited by 295
Martinez, J.-C. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.3.301 · Cited by 269
Farasat, S., Yu, S. S., Neel, V. A., Nehal, K. S., Lardaro, T., Mihm, M. C., Byrd, D. R., Balch, C. M., Califano, J. A., Chuang, A. Y., et al. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.08.033 · Cited by 237
Veness, M. J., Quinn, D. I., Ong, C. S., Keogh, A. M., Macdonald, P. S., Cooper, S. G., & Morgan, G. W. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990415)85:8<1758::aid-cncr16>3.0.co;2-f · Cited by 214
Metastatic Cutaneous Squamous Cell Carcinoma: An Update
WEINBERG, A. S., OGLE, C. A., & SHIM, E. K. (2007) · Dermatologic Surgery · doi:10.1111/j.1524-4725.2007.33190.x · Cited by 200
Cited by
Karia, P. S., Han, J., & Schmults, C. D. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.11.037 · Cited by 829
Self-citationCutaneous squamous cell carcinoma
Que, S. K. T., Zwald, F. O., & Schmults, C. D. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.08.059 · Cited by 793
Self-citationGuidelines of care for the management of cutaneous squamous cell carcinoma
Alam, M., Armstrong, A., Baum, C., Bordeaux, J. S., Brown, M., Busam, K. J., Eisen, D. B., Iyengar, V., Lober, C., Margolis, D. J., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.10.007 · Cited by 596
Thompson, A. K., Kelley, B. F., Prokop, L. J., Murad, M. H., & Baum, C. L. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.4994 · Cited by 521
Stratigos, A., Garbe, C., Lebbe, C., Malvehy, J., del Marmol, V., Pehamberger, H., Peris, K., Becker, J. C., Zalaudek, I., Saiag, P., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.06.110 · Cited by 514
Metadata
- Authors
- Jambusaria-Pahlajani, A., Kanetsky, P. A., Karia, P. S., Hwang, W.-T., Gelfand, J. M., Whalen, F. M., Elenitsas, R., Xu, X., & Schmults, C. D.
- Venue
- JAMA Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2013-04-01
- Volume
- 149
- Issue
- 4
- Pages
- 402
- ISSN
- 2168-6068 (ISSN-L)
- OpenAlex
- W2146086092
- Cited by
- 365
- References
- 11
- FWCI
- 15.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.